Directorate change
Directorate change
February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:
|
Director |
Appointment |
Resignation |
|
Dominic Blakemore |
Remuneration Committee |
N/A |
|
Olivier Bohuon |
Nomination & Governance Committee |
Science & Technology Committee |
|
Ian Clark |
Remuneration Committee; |
N/A |
|
Sara Mathew |
Nomination & Governance Committee |
Remuneration Committee |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Debbi Ford | [email protected] | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.